| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website http://www.jocmr.org |
Review
Volume 8, Number 3, March 2016, pages 181-189
Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma
Table
| Therapeutic agent | Patients, N | OR rate, N, % | PR rate, N, % | CR rate, N, % | Reference |
|---|---|---|---|---|---|
| OR rate: objective response rate; PR rate: partial response rate; CR rate: complete response rate. | |||||
| Doxorubicin | 41(28 evaluable) | 7/28, 25% | NA | NA | Omura et al [15] |
| Bevacizumab + doxorubicin | 7 | 2/7, 28% | 2/7, 28% | 0/7, 0% | D’Adamo et al [16] |
| Doxorubicin + dimethyl-triazeno-imidazole-carboxamide (DTIC) | 31(20 evaluable) | 6/20, 30% | NA | NA | Omura et al [15] |
| Trabectedin | 3 | 1/3, 33% | 1/3, 33% | 0/5, 0% | Amant et al [22] |
| Trabectedin | 52 | NA | 11/52, 21% | NA | Grosso et al [21] |
| Gemcitabine | 42 | 9/42, 21% | 8/42, 19% | 1/42, 2% | Look et al [9] |
| Gemcitabine + docetaxel | 23 | Not reached after 49 months | NA | NA | Hensley et al [10] |
| Gemcitabine +docetaxel (first line) | 42 (39 evaluable) | 15/39, 38% | 13/39, 33% | 2/39, 5% | Hensley et al [11] |
| Gemcitabine + docetaxel (second line) | 48 | 13/48, 27% | 10/48, 20% | 3/48, 6% | Hensley et al [12] |
| Ifosfamide + doxorubicin | 33 | 10/33, 30% | 9/33, 27% | 1/33, 3% | Sutton et al [18] |
| Mitomycin, doxorubicin, and cisplatin | 35 | 8/35, 22% | 5/35, 14% | 3/35, 8% | Edmonson et al [13] |
| Sunitinib | 23 | 2/23, 8% | 2/23, 8% | 0/23, 0% | Hensley et al [20] |
| Thalidomide | 29 | 0/29, 0% | 0/29, 0% | 0/29, 0% | McMeekin et al [19] |
| Topotecan | 36 | 4/36, 11% | 3/36, 8.4% | 1/36, 2.7% | Miller et al [14] |